Hepatitis B surface antigen loss in chronic hepatitis B patients with low-viral-load.
HBV
HBeAg
HBsAg
NAs
viral load
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
revised:
29
05
2024
received:
03
04
2024
accepted:
12
06
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
Among low viral load (DNA of hepatitis B virus (HBV) was < 2000 IU/mL), the factor of the loss of hepatitis B surface antigen (HBsAg) remained elusive. The retrospective study recruited patients with chronic hepatitis B (CHB) who were negative low for hepatitis B e-antigen (HBeAg), had a low viral load, and experienced HBsAg loss during follow-up. CHB patients with low-viral load but without consequent HBsAg loss were also enrolled at the ratio of 1:4. The factors contributing to HBsAg loss were analyzed. A total of 80 patients were recruited for the current study, with a mean age of 63.9 years and 61.3% being male. Among them, 62.5% patients (50/80) were treated with potent nucleoside/nucleotide analogues (NAs) during the follow-up period. Additionally, 12.5% patients (10/80) had a prior history of NAs treatment before enrolment. During the follow-up, HBsAg loss occurred in 17 patients (21.3%). Compared with patients without HBsAg loss, those with HBsAg loss were younger (57.9 years vs 65.5 years; P = 0.01), had lower HBV DNA levels (1.3 log In the study, older age and prior NAs were positively associated with HBsAg loss, and current NAs was negatively associated with HBsAg loss. Additionally, some patients experienced HBsAg loss during the NAs therapy.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Among low viral load (DNA of hepatitis B virus (HBV) was < 2000 IU/mL), the factor of the loss of hepatitis B surface antigen (HBsAg) remained elusive.
METHODS
METHODS
The retrospective study recruited patients with chronic hepatitis B (CHB) who were negative low for hepatitis B e-antigen (HBeAg), had a low viral load, and experienced HBsAg loss during follow-up. CHB patients with low-viral load but without consequent HBsAg loss were also enrolled at the ratio of 1:4. The factors contributing to HBsAg loss were analyzed.
RESULTS
RESULTS
A total of 80 patients were recruited for the current study, with a mean age of 63.9 years and 61.3% being male. Among them, 62.5% patients (50/80) were treated with potent nucleoside/nucleotide analogues (NAs) during the follow-up period. Additionally, 12.5% patients (10/80) had a prior history of NAs treatment before enrolment. During the follow-up, HBsAg loss occurred in 17 patients (21.3%). Compared with patients without HBsAg loss, those with HBsAg loss were younger (57.9 years vs 65.5 years; P = 0.01), had lower HBV DNA levels (1.3 log
CONCLUSIONS
CONCLUSIONS
In the study, older age and prior NAs were positively associated with HBsAg loss, and current NAs was negatively associated with HBsAg loss. Additionally, some patients experienced HBsAg loss during the NAs therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Health and Welfare
Organisme : Pingtung Hospital
Organisme : Kaohsiung Medical University Hospital
Organisme : National Science Council of Taiwan
ID : NSTC 112-2923-B-037-002-MY3
Organisme : National Pingtung University of Science and Technology
Organisme : Kaohsiung Medical University
ID : NPUST kmU-111-P009
Informations de copyright
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Janevska D, Chaloska‐Ivanova V, Janevski V. Hepatocellular carcinoma: risk factors, diagnosis and treatment. Open Access Maced. J. Med. Sci. 2015; 3: 732–736.
Yang JF, Lin CI, Huang JF et al. Viral hepatitis infections in southern Taiwan: a multicenter community‐based study. Kaohsiung J. Med. Sci. 2010; 26: 461–469.
Jang TY, Liang PC, Liu TW et al. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. J. Chin. Med. Assoc. 2021; 84: 255–260.
Hu YC, Yeh CC, Chen RY et al. Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program. PeerJ. 2018; 6: e4297.
Grossi G, Vigano M, Loglio A, Lampertico P. Hepatitis B virus long‐term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 2017; 37: 45–51.
Jang TY. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues. Aliment. Pharmacol. Ther. 2023; 57: 587–588.
Chien RN, Kao JH, Peng CY et al. Taiwan consensus statement on the management of chronic hepatitis B. J. Formos. Med. Assoc. 2019; 118: 7–38.
Wang J, Yan X, Zhu L et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment. Pharmacol. Ther. 2023; 57: 464–474.
Jang TY, Wei YJ, Liu TW et al. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci. Rep. 2021; 11: 8184.
Hsu YC, Wong GL, Chen CH et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an International Consortium of Chronic Hepatitis B. Am. J. Gastroenterol. 2020; 115: 271–280.
Terrault NA, Wahed AS, Feld JJ et al. Incidence and prediction of HBsAg seroclearance in a prospective multi‐ethnic HBeAg‐negative chronic hepatitis B cohort. Hepatology 2022; 75: 709–723.
Lin YY, Huang JF, Liu SF et al. Performance characteristics of two real‐time PCR assays for quantification of hepatitis B virus DNA. Scand. J. Infect. Dis. 2009; 41: 614–618.
Huber A, Ebner L, Heverhagen JT, Christe A. State‐of‐the‐art imaging of liver fibrosis and cirrhosis: a comprehensive review of current applications and future perspectives. Eur. J. Radiol. Open. 2015; 2: 90–100.
Bruix J, Sherman M, American Association for the Study of Liver Diseases, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
Jang TY, Wei YJ, Yeh ML et al. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. J. Formos. Med. Assoc. 2021; 120: 303–310.
Jang TY, Ho CC, Wu CD, Dai CY, Chen PC. Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Medicine 2023; 102: e34276.
Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin. Mol. Hepatol. 2022; 28: 276–331.
Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.
Hsu YS, Chien RN, Yeh CT et al. Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522–1527.
Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long‐term follow‐up. Hepatology 2007; 45: 1187–1192.
Cao Z, Liu Y, Ma L et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha. Hepatology 2017; 66: 1058–1066.
de Niet A, Jansen L, Stelma F et al. Peg‐interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open‐label trial. Lancet Gastroenterol. Hepatol. 2017; 2: 576–584.
Ferreira SC, Chacha SG, Souza FF et al. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ann. Hepatol. 2014; 13: 762–770.
Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10‐year follow‐up of 673 patients. Eur. J. Gastroenterol. Hepatol. 2015; 27: 638–643.
Barcena Marugan R, Garcia Garzon S. DNA‐guided hepatitis B treatment, viral load is essential, but not sufficient. World J. Gastroenterol. 2009; 15: 423–430.
Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019; 5: 30–36.
Yim HJ, Kim JH, Park JY et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin. Mol. Hepatol. 2020; 26: 411–429.
Zhu X, Wang LC, Chen EQ et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB‐4 in patients with chronic HBV infection. Dig. Dis. Sci. 2011; 56: 2742–2749.
Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction‐associated fatty liver disease: challenges and perspectives. Clin. Mol. Hepatol. 2023; 29: 320–331.